No connection

Search Results

IVVD vs PIII

IVVD
Invivyd, Inc.
BEARISH
Price
$1.76
Market Cap
$497.7M
Sector
Healthcare
AI Confidence
90%
PIII
P3 Health Partners Inc.
BEARISH
Price
$2.50
Market Cap
$507.9M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
IVVD
--
PIII
--
Forward P/E
IVVD
-8.0
PIII
-11.9
P/B Ratio
IVVD
2.05
PIII
-0.05
P/S Ratio
IVVD
9.31
PIII
0.35
EV/EBITDA
IVVD
-4.98
PIII
-1.53

Profitability

Gross Margin
IVVD
92.99%
PIII
-4.12%
Operating Margin
IVVD
-72.96%
PIII
-39.98%
Profit Margin
IVVD
-98.25%
PIII
-10.14%
ROE
IVVD
-33.97%
PIII
-6952.57%
ROA
IVVD
-17.09%
PIII
-23.46%

Growth

Revenue Growth
IVVD
24.5%
PIII
3.8%
Earnings Growth
IVVD
--
PIII
--

Financial Health

Debt/Equity
IVVD
0.01
PIII
--
Current Ratio
IVVD
7.24
PIII
0.24
Quick Ratio
IVVD
7.06
PIII
0.22

Dividends

Dividend Yield
IVVD
--
PIII
--
Payout Ratio
IVVD
0.0%
PIII
0.0%

AI Verdict

IVVD BEARISH

Invivyd exhibits critical financial weakness, highlighted by a Piotroski F-Score of 0/9, indicating a complete lack of fundamental improvement across all measured categories. While the company maintains a strong liquidity position with a Current Ratio of 7.24 and very low debt, it is suffering from extreme operational inefficiency with a profit margin of -98.25%. There is a stark disconnect between the analyst 'Strong Buy' consensus (Target $10.00) and the deterministic data, which shows consistent earnings misses and bearish insider activity.

Strengths
High Gross Margin (92.99%) suggesting strong product pricing potential
Strong short-term liquidity with a Current Ratio of 7.24
Very low leverage with a Debt/Equity ratio of 0.01
Risks
Severe operational losses with a profit margin of -98.25%
Deterministic health failure (Piotroski F-Score 0/9)
Consistent failure to meet earnings estimates (1/4 beats in last 4 quarters)
PIII BEARISH

P3 Health Partners exhibits severe financial distress, characterized by a Piotroski F-Score of 4/9 which barely maintains a 'stable' rating despite catastrophic balance sheet metrics. The company is operating with negative equity (Price/Book: -0.05) and a critical liquidity crisis, evidenced by a Current Ratio of 0.24. Massive operating losses and a staggering ROE of -6952.57% indicate a failing business model. With a 5-year price decline of 99.5% and consistent earnings misses, the company faces significant insolvency risk.

Strengths
Low Price-to-Sales ratio (0.35) suggests low valuation relative to revenue
Marginal positive revenue growth (3.80% YoY)
Analyst target price ($3.50) sits above current market price
Risks
Critical liquidity shortage with a Current Ratio of 0.24
Negative shareholder equity (Price/Book -0.05)
Extreme operational inefficiency with -39.98% operating margins

Compare Another Pair

IVVD vs PIII: Head-to-Head Comparison

This page compares Invivyd, Inc. (IVVD) and P3 Health Partners Inc. (PIII) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile